Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura
Acquired thrombotic thrombocytopenic purpura (TTP) is an autoimmune disorder resulting in potentially life-threating systemic thrombotic microangiopathy due to production of antibodies directed against the von Willebrand factor-cleaving protease ADAMTS13. Typically managed with plasma exchange, glucocorticoids, and the first-generation anti-CD20 monoclonal antibody rituximab, patients with multiple relapses or refractory disease present unique management challenges. We describe a case of a young woman with multiple relapses of TTP despite standard therapy who was treated with ofatumumab, a second-generation anti-CD20 monoclonal antibody, after developing a severe hypersensitivity reaction to rituximab precluding its use. Ofatumumab was effective for the treatment of an acute relapse of TTP in combination with plasmapheresis and as a single-agent for prophylaxis. The patient has had no evidence of relapse 2 years after completion of acute treatment and 1 year after completing prophylactic therapy. Hypersensitivity to ofatumumab did not develop.
KeywordsThrombotic thrombocytopenic purpura Ofatumumab Drug hypersensitivity Rituximab Prophylaxis
HAS collected the data, analyzed and interpreted the data, and wrote/revised the manuscript; RF Grace revised the manuscript; JM Connors designed the report and critically revised the manuscript.
Compliance with ethical standards
Conflict of interest
Al-Samkari, H: Consultancy (Agios Pharmaceuticals); Grace, R: Research Funding, Consultancy, Scientific Advisory Board (Agios Pharmaceuticals); Connors, JM: (Boehringer Ingelheim: Scientific Advisory Board; Bristol-Myers Squibb: Scientific Advisory Board, Consultant, Independent Review Committee; Unum Therapeutics: Data Safety Monitoring Board).
Research involving human and animal participants
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. New Engl J Med 325(6):393–397. https://doi.org/10.1056/NEJM199108083250604 CrossRefPubMedGoogle Scholar
- 2.Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M (2013) Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 11(3):481–490. https://doi.org/10.1111/jth.12114 CrossRefPubMedGoogle Scholar
- 5.Beloncle F, Buffet M, Coindre JP, Munoz-Bongrand N, Malot S, Pene F, Mira JP, Galicier L, Guidet B, Baudel JL, Subra JF, Tanguy-Schmidt A, Pourrat J, Azoulay E, Veyradier A, Coppo P, Thrombotic Microangiopathies Reference C (2012) Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA reference center experience. Transfusion 52 (11):2436–2444. https://doi.org/10.1111/j.1537-2995.2012.03578.x CrossRefPubMedGoogle Scholar
- 7.Cataland SR, Jin M, Ferketich AK, Kennedy MS, Kraut EH, George JN, Wu HM (2007) An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 136(1):146–149. https://doi.org/10.1111/j.1365-2141.2006.06384.x CrossRefPubMedGoogle Scholar
- 9.Cataland SR, Kourlas PJ, Yang S, Geyer S, Witkoff L, Wu H, Masias C, George JN, Wu HM (2017) Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. Blood Adv 1(23):2075–2082. https://doi.org/10.1182/bloodadvances.2017009308 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigon MDC, Ogura M, Leppa S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A (2017) Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol 35(5):544–551. https://doi.org/10.1200/JCO.2016.69.0198 CrossRefPubMedGoogle Scholar
- 12.van Oers MH, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S, Levin MD, Gupta I, Phillips J, Williams V, Manson S, Lisby S, Geisler C, Investigators Ps (2015) Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 16(13):1370–1379. https://doi.org/10.1016/S1470-2045(15)00143-6 CrossRefPubMedGoogle Scholar
- 13.Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ (2011) A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 118(7):1746–1753. https://doi.org/10.1182/blood-2011-03-341131 CrossRefPubMedGoogle Scholar
- 15.Hie M, Gay J, Galicier L, Provot F, Presne C, Poullin P, Bonmarchand G, Wynckel A, Benhamou Y, Vanhille P, Servais A, Bordessoule D, Coindre JP, Hamidou M, Vernant JP, Veyradier A, Coppo P, French Thrombotic Microangiopathies Reference C (2014) Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 124 (2):204–210. https://doi.org/10.1182/blood-2014-01-550244 CrossRefPubMedGoogle Scholar